Lenvatinib Mesylate CAS 857890-39-2 Assay 98.0~102.0% Pabrik
Ruifu Kimia Supply Lenvatinib Mesylate panengah Jeung Purity High
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Métil 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Métil 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimétil-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Métil 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Ngaran Kimia | Lenvatinib Mesylate |
sinonim | 4-[3-Chloro-4-[(cyclopropylaminocarbonyl)amino]phenoxy]-7-Methoxy-6-Quinolinecarboxamide Mesylate;E 7080 Mésylate;Lenvima |
Nomer CAS | 857890-39-2 |
Nomer CAT | RF-PI1975 |
Status saham | Dina Stok, Skala Produksi Nepi ka Ton |
Formula Molekul | C21H19N4O4Cl.CH4O3S |
Beurat Molekul | 522.96 |
merek | Kimia Ruifu |
Barang | spésifikasi |
Penampilan | Bodas ka Pareum-Bodas Bubuk atanapi Kristal |
Idéntifikasi | Ku IR;Ku UV;Ku HPLC |
Kalarutan | Rada Leyur dina Cai, Praktis Teu Leyur dina Étanol |
Titik lebur | 228,0 ~ 230,0 ℃ |
Kandungan Cai (KF) | <1,00% |
Résidu on Ignition | <0,10% |
Logam beurat | <20ppm |
Zat Patali | |
Sakur Najis Tunggal | <0,50% |
Total Kotoran | <1,00% |
Métode Assay / Analisis | 98.0~102.0% (Dasar HPLC dina Pangeringan) |
Kapadetan Bulk | 0,40gm/ml~0,60gm/ml |
Standar tés | Standar Perusahaan |
Pamakéan | API |
Bungkusan: Botol, kantong Aluminium foil, 25kg / Karton Drum, atawa nurutkeun sarat customer urang
Kaayaan Panyimpenan:Simpen dina wadah anu disegel dina tempat anu tiis sareng garing;Ngajaga tina cahaya sareng Uap
Lenvatinib Mesylate (CAS: 857890-39-2) mangrupikeun inhibitor lisan sareng multi-sasaran VEGFR1-3, FGFR1-4, PDGFR, KIT, sareng RET, kalayan kagiatan antitumor anu kuat.Lenvatinib Mesylate mangrupakeun reséptor tirosin kinase (RTK) inhibitor nu boga selectivity pikeun VEGFR2.Éta nunjukkeun kagiatan antineoplastik, sareng parantos dituduhkeun pikeun pengobatan pasien anu kambuh sacara lokal atanapi métastatik, progresif, yodium radioaktif (RAI) -refractory kanker tiroid diferensiasi.Lenvatinib Mesylate munggaran disatujuan ku Administrasi Pangan sareng Narkoba AS (FDA) dina 13 Pebruari 2015, teras disatujuan ku Badan Farmasi sareng Alat Médis Jepang (PMDA) dina 26 Mar 2015, sareng disatujuan ku Badan Kedokteran Éropa (EMA) dina 28 Mei 2015. Ieu dimekarkeun sarta dipasarkan salaku Lenvima® ku Eisai.Lenvatinib Mesylate mangrupikeun inhibitor tirosin kinase sababaraha reséptor lisan kalayan mode beungkeutan unik anu sacara selektif ngahambat kagiatan kinase tina reséptor faktor pertumbuhan endothelial vaskular (VEGF), salian ti kinase tirosin anu aya hubunganana sareng proangiogenik sareng onkogenik anu disangka kalibet dina proliferasi tumor. .Hal ieu dituduhkeun pikeun pengobatan kanker tiroid diferensiasi radioiodine-refractory progresif.Lenvimadianggo sorangan pikeun ngubaran kanker tiroid anu béda (DTC), jinis kanker tiroid anu henteu tiasa diubaran ku yodium radioaktif sareng kamajuan.LENVIMA dipaké babarengan jeung ubar séjén disebut everolimus pikeun ngubaran sawawa mibanda tipe kanker ginjal disebut carcinoma sél renal canggih (RCC) sanggeus hiji kursus perlakuan jeung ubar anti kanker sejen.